CareDx Inc.

CareDx Inc. is a leading precision medicine company that discovers, develops, and commercializes clinically differentiated diagnostic solutions for transplant patients and caregivers. It specializes in genomics-based testing services, including AlloSure Kidney and AlloSure Heart for donor-derived cell-free DNA surveillance in kidney and heart transplant patients, AlloMap Heart as a gene expression test for heart transplants, and AlloSure Lung for lung transplants. The company also provides high-quality lab products like HLA typing solutions such as AlloSeq Tx, Olerup SSP, and AlloSeq cfDNA to improve donor-recipient matching for organs and stem cells. Complementing these, CareDx Inc. offers digital transplant solutions through platforms like Ottr for patient surveillance and EMR integration, XynManagement for quality improvement and care coordination, and mobile apps such as AlloCare and Transplant Hero for medication adherence and health monitoring. Operating primarily in the healthcare sector with a focus on testing services, products, patient solutions, and pharma services, CareDx Inc. supports transplant centers, clinicians, and biopharma partners across the pre- and post-transplant journey. Founded in 1998 and headquartered in Brisbane, California, it plays a key role in advancing transplant outcomes through non-invasive molecular testing and innovative technologies.

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. John Walter Hanna Jr.

Employees

644

Headquarters

South San Francisco, CA, United States

Website

caredx.com